D.Western Therapeutics Institute,Inc.is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide.

Product Pipeline

Product Pipeline

As of Mar 2018

DWTI Product Pipeline

pipeline_en

※1 The domestic pharmaceutical company have option rights in the whole world except Japan of H-1129, now the company is evaluating.
※2 K-134 has been targeted arteriosclerosis obliterans as indication, developed and completed phase 2 by Kowa Company, Ltd.. Meanwhile, Kowa is now considering another target disease.

pdficon_large544KB(Enlarge the above diagram)

GLANATEC® ophthalmic solution 0.4% ▶Learn more

WP-1303(H-1129) ▶Learn more

H-1337 ▶Learn more

K-134 ▶Learn more

DW-1002 ▶Learn more

Japan Innovative Therapeutics, Inc. Product Pipeline

pipeline_1705_en

pdficon_large108KB(Enlarge the above diagram)

PAGETOP
D.Western Therapeutics Institute, Inc.
1-18-11, Nishiki, Naka-ku,
Nagoyashi, Aichi 460-0003 Japan
TEL 81+52-218-8785
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.